Feeds

Pharma industry could benefit from elephant man report

First-in-man trials to be conducted in hospital

Intelligent flash storage arrays

The recommendations published in the wake of the disastrous drug trial that left six young men hospitalised could actually benefit some parts of the UK pharma industry, according to one expert.

A report by the Expert Scientific Group into the trial has just been published. Though the report has been called a whitewash by lawyers acting for the men, Louise Fullwood, a lawyer specialising in life sciences at Pinsent Masons, the law firm behind OUT-LAW, denied that claim, and said it could benefit UK companies and universities.

"This is a sensible report, it is not a whitewash," she said. Fullwood said the report will benefit hospitals, bringing in additional much needed testing and research funding.

"He is saying that when drugs are being given to people for the first time it should be done in centres that are based either in hospitals or in private sector units but based within or very close to a hospital, so that you have intensive care and treatment facilities and you need to have 24-hour medical cover there.

"Some of the private sector sites that are not necessarily that close to a hospital are not necessarily the places to do first-in-man testing, so that's good news for hospitals in this country that have on site testing facilities or an ability to do it in their own labs and their own wards because that's extra business for them," she said.

"First-in-man studies of higher risk medicines should always be conducted in an appropriate clinical environment supervised by staff with appropriate levels of training and expertise, with immediate access to facilities for the treatment and stabilisation of individuals in an acute emergency, and with pre-arranged contingency availability of ITU [intensive care / therapy unit] facilities in reasonable proximity," said the report. First-in-man studies are those in which a medicine tested on animals is given to humans for the first time.

According to Fullwood, clinical research is a vital element in research funding of hospitals and universities. "It's a big revenue generator and it very much helps funding pure blue skies scientific research in this country because researchers can get funds by carrying out these trials which they can then use to carry out perhaps more interesting pure research," she said.

The report dealt with the case of six young men who submitted to voluntary tests of the drug TGN1412 at a private testing facility at Northwick Park Hospital earlier this year. The test was carried out by Parexel on behalf of TeGenero, a German firm that has became insolvent because it was not fully insured against the adverse affects of the test.

The drug was designed to treat rheumatoid arthritis, leukemia and multiple sclerosis, but it caused a horrific reaction in all six healthy men. They swelled up, in one case to three times his normal body size, and some lost numerous fingers and toes. The men have been warned that they have a greatly increased chance of developing cancer and immune system disorders in later life.

The body responsible for the regulation of the sector is the Medicines and Healthcare Regulatory Agency. "Clinical trials in general have an excellent safety record, but it is important that we learn the lessons from the TGN1412 incident," said its chief executive Professor Kent Woods.

The Expert Science Group was appointed by the government to investigate the process. Chaired by molecular medicine expert Professor Gordon Duff, it found that a total overhaul of existing rules was not needed, and that some of the problems in the Northwick trial related to failures to follow existing rules.

"They did pick up on some problems with the trial itself but they were where people were ignoring or not conforming with existing regulation so it's arguable we don't need additional regulation we just need people to pay attention to the ones that are already there," said Fullwood.

The report is vital for the pharmaceutical testing industry, a major UK industry that is seen as being reluctant to embrace further regulation.

"The UK clinical research and pharmaceutical industry is one of the best regulated in the world, it has very high standards, that's why it takes 10 or 15 years to get a drug to market," said Fullwood. "If the regulator were to slap on a whole new set of regulations and make it even more regulated then there's a risk that pharmaceutical companies would say it's no longer cost effective to carry out research work in the UK, let's take it to Latin America or somewhere that's less regulated and that would be very bad for UK hospitals, universities and clinical research organisations."

See: The report (110 page/1.4MB PDF)

Copyright © 2006, OUT-LAW.com

OUT-LAW.COM is part of international law firm Pinsent Masons.

Internet Security Threat Report 2014

More from The Register

next story
Renewable energy 'simply WON'T WORK': Top Google engineers
Windmills, solar, tidal - all a 'false hope', say Stanford PhDs
Bond villains lament as Wicked Lasers withdraw death ray
Want to arm that shark? Better get in there quick
The next big thing in medical science: POO TRANSPLANTS
Your brother's gonna die, kid, unless we can give him your, well ...
SEX BEAST SEALS may be egging each other on to ATTACK PENGUINS
Boffin: 'I think the behaviour is increasing in frequency'
NASA launches new climate model at SC14
75 days of supercomputing later ...
Britain's HUMAN DNA-strewing Moon mission rakes in £200k
3 days, and Kickstarter moves lander 37% nearer takeoff
Reuse the Force, Luke: SpaceX's Elon Musk reveals X-WING designs
And a floating carrier for recyclable rockets
Simon's says quantum computing will work
Boffins blast algorithm with half a dozen qubits
prev story

Whitepapers

Choosing cloud Backup services
Demystify how you can address your data protection needs in your small- to medium-sized business and select the best online backup service to meet your needs.
Getting started with customer-focused identity management
Learn why identity is a fundamental requirement to digital growth, and how without it there is no way to identify and engage customers in a meaningful way.
10 threats to successful enterprise endpoint backup
10 threats to a successful backup including issues with BYOD, slow backups and ineffective security.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.
The hidden costs of self-signed SSL certificates
Exploring the true TCO for self-signed SSL certificates, including a side-by-side comparison of a self-signed architecture versus working with a third-party SSL vendor.